Global Next Generation Sequencing (NGS) Market – Industry Trends and Forecast to 2031

>Global Next Generation Sequencing (NGS) Market, By Product & Service (Consumables, Services, and Instruments), Technology (Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), and Others), Application (Pharmaceuticals Microbiology, Drug & Biomarker Discovery, Diagnostics, Precision Medicine, Agricultural & Animal Research, Food Pathogen Screening, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinics, Clinical Laboratories, Contract Research Organizations (CROS), and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.

Прогнозный период 2025 - 2032

CAGR 15.10%

Размер рынка в 2024 году USD 15.98 Billion

Размер рынка в 2032 году USD 49.21 Billion

Динамика размера рынка

2024 USD 15.98 Billion

2028 USD 28.05 Billion

2032 USD 49.21 Billion

Региональное лидерство

Охват рынка Global

Ключевые игроки

IlluminaInc.
Thermo Fisher Scientific Inc.
QIAGEN
Merck KGaA
Charles River Laboratories

Medical Devices
Global
350 страниц
Количество таблиц: 825
Количество рисунков: 40
Последнее обновление: 21 апреля 2025

Global Next Generation Sequencing (NGS) Market, By Product & Service (Consumables, Services, and Instruments), Technology (Sequencing by Synthesis (SBS), Sequencing by Ligation (SBL), and Others), Application (Pharmaceuticals Microbiology, Drug & Biomarker Discovery, Diagnostics, Precision Medicine, Agricultural & Animal Research, Food Pathogen Screening, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals & Clinics, Clinical Laboratories, Contract Research Organizations (CROS), and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2031.

Каков размер рынка и темпы роста следующего поколения (NGS)

Согласно анализу рынка Data Bridge Market Research, глобальный рынок секвенирования следующего поколения (NGS) был оценен как один из лучших.15,98 млрд долларов в 2024 годуОжидается, что он достигнет49,21 млрд долларов к 2032 году
В течение прогнозируемого периода с 2025 по 2032 год рынок, скорее всего, будет расти.CAGR 15.10%В первую очередь, благодаря постоянным достижениям в технологиях секвенирования и расширению клинических применений.
Ключевыми факторами этого роста являются рост заболеваемости генетическими нарушениями, растущий спрос на персонализированную медицину и растущее внедрение НГС в онкологию и репродуктивное здоровье.

Размер рынка и прогноз

Глобальная рыночная стоимость (2024):15,98 млрд долларов
Ожидаемая рыночная стоимость (2032):$ 49,21 млрд.
Прогноз CAGR (2024-2032): 15.10%

Секвенирование следующего поколения (NGS) Анализ рынка

Технологии секвенирования нового поколения (NGS) являются преобразующими инструментами вгеномикаЭто обеспечивает быстрое, точное и экономически эффективное секвенирование ДНК и РНК. Они широко используются в исследованиях, клинической диагностике и персонализированной медицине, играя решающую роль в таких областях, как геномика рака, обнаружение редких заболеваний и наблюдение за инфекционными заболеваниями.
Спрос на NGS в значительной степени обусловлен растущей распространенностью генетических расстройств, рака и рака.инфекционные заболеванияНаряду с растущей потребностью в точной медицине. Расширение использования NGS в неинвазивном пренатальном тестировании (NIPT) и сопутствующей диагностике также поддерживает рост рынка.
Регион Северной Америки выделяется как один из ведущих рынков для NGS, что объясняется его сильной исследовательской инфраструктурой, значительным финансированием исследований в области геномики и ранним внедрением передовых технологий.
- Например, в США наблюдается всплеск клинического использования тестов на основе NGS, что обусловлено такими инициативами, как Инициатива по точной медицине и расширенные одобрения FDA для диагностики NGS. В регионе также находятся крупные игроки рынка и ведущие исследовательские институты геномики.
Во всем мире платформы NGS являются одним из наиболее важных компонентов в современных лабораториях геномики и молекулярной биологии, уступая только высокопроизводительным системам ПЦР, и необходимы для внедрения инноваций в секторах здравоохранения, биотехнологий и академических исследований.

Сегментация рынка отчетов и секвенирование следующего поколения (NGS)

Атрибуты	Next Generation Sequencing (NGS) Ключевые идеи рынка
Сегменты покрыты	By Продукты и услуги: расходные материалы, услуги и инструменты By Технология:Секвенирование с помощью синтеза (SBS), секвенирование с помощью лигирования (SBL) и другие С помощью приложения:Фармацевтическая микробиология, открытие лекарств и биомаркеров, диагностика, точная медицина, сельскохозяйственные и исследования на животных, скрининг пищевых патогенов и другие By Конечный пользователь:Фармацевтические и биотехнологические компании, академические и исследовательские институты, больницы и клиники, клинические лаборатории, контрактные исследовательские организации (CROS) и другие Дистрибьюторский каналПрямой тендер, розничные продажи и другие
Страны, охваченные	Северная Америка США. Канада Мексика Европа Германия Франция Великобритания. Нидерланды Швейцария Бельгия Россия Италия Испания Турция Остальная Европа Азиатско-Тихоокеанский регион Китай Япония Индия Южная Корея Сингапур Малайзия Австралия Таиланд Индонезия Филиппины Остальная часть Азиатско-Тихоокеанского Ближний Восток и Африка Саудовская Аравия У.А.Е. Южная Африка Египет Израиль Остальная часть Ближнего Востока и Африки Южная Америка Бразилия Аргентина Остальная часть Южной Америки
Ключевые игроки рынка	Illumina, Inc. (США) Thermo Fisher Scientific (США) Pacific Biosciences of California, Inc. (США) Oxford Nanopore Technologies (Великобритания) BGI Group (Китай) MGI Tech (Китай) Roche Sequencing Solutions (Швейцария) Agilent Technologies (США) PerkinElmer, Inc. (США) Bio-Rad Laboratories, Inc. (США) QIAGEN N.V. (Германия) Genomics PLC (Великобритания) Genedata (Швейцария) Roche NimbleGen (Швейцария) Macrogen, Inc. (Южная Корея) Novogene Corporation (Китай) GATC Biotech AG (Германия) BaseClear B.V. (Нидерланды) Fasteris SA (Швейцария) Dovetail Genomics (США)
Рыночные возможности	Расширение НГС в клинической диагностике Растущий спрос на развивающихся рынках Растущее использование NGS в эпиднадзоре за инфекционными заболеваниями
Информационные наборы данных с добавленной стоимостью	В дополнение к информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географическое покрытие и основные игроки, рыночные отчеты, курируемые Data Bridge Market Research, также включают углубленный экспертный анализ, эпидемиологию пациентов, анализ трубопроводов, анализ цен и нормативную базу.

Каковы основные тенденции на рынке секвенирования следующего поколения (NGS)

«Интеграция ИИ и облачной аналитики в рабочие процессы NGS»

Одной из заметных тенденций на мировом рынке секвенирования следующего поколения (NGS) является растущая интеграция искусственного интеллекта (ИИ) и облачных платформ для анализа и интерпретации данных.
Эти технологии повышают скорость, точность и масштабируемость обработки геномных данных, облегчая получение значимых клинических и исследовательских данных из огромного количества данных секвенирования.
- Например, алгоритмы на основе ИИ в настоящее время используются для обнаружения мутаций, прогнозирования рисков заболеваний и оптимизации классификации вариантов, что значительно сокращает время разворота в клинической геномике.
Облачные платформы также поддерживают сотрудничество между исследователями и клиницистами в режиме реального времени, обеспечивая безопасное хранение, обмен и анализ больших наборов геномных данных в разных учреждениях и регионах.
Эта тенденция меняет ландшафт геномики за счет повышения эффективности, снижения затрат и расширения доступа к технологиям NGS, особенно в децентрализованных и удаленных медицинских учреждениях.

Секвенирование следующего поколения (NGS) динамика рынка

водитель

«Повышение распространенности генетических расстройств и хронических заболеваний»

Растущее глобальное бремя генетических расстройств, рака и хронических заболеваний является одним из наиболее значительных факторов, стимулирующих спрос на технологии секвенирования следующего поколения (NGS).
NGS обеспечивает высокую пропускную способность и точный анализ генетических мутаций, что делает его важным инструментом в ранней диагностике, оценке риска заболеваний и выборе лечения, особенно при таких состояниях, как рак, редкие наследственные расстройства и сердечно-сосудистые заболевания.
По мере того, как растет осведомленность о персонализированной и точной медицине, системы здравоохранения и исследовательские учреждения обращаются к NGS, чтобы адаптировать стратегии лечения на основе отдельных генетических профилей, тем самым улучшая результаты и уменьшая методы проб и ошибок в терапии.
Текущие достижения в платформах NGS, такие как более высокая точность, более быстрое время обработки и снижение затрат, еще больше ускоряют его внедрение в клинических и исследовательских приложениях.
Поскольку генетические заболевания становятся все более признанными во всех возрастных группах и регионах, все больше внимания уделяется интеграции геномного тестирования в рутинные рабочие процессы здравоохранения.

Например,

В сентябре 2022 года Всемирная организация здравоохранения (ВОЗ) сообщила, что генетические нарушения способствуют более 30% госпитализаций педиатров в некоторых странах. Это подчеркивает необходимость использования инструментов раннего геномного скрининга, таких как NGS, для ранней диагностики и планирования лечения.
В июле 2023 года, по данным Global Genes Foundation, известно более 7000 редких генетических заболеваний, многие из которых до сих пор не диагностированы из-за отсутствия доступного тестирования. NGS позиционируется как мощное решение для преодоления этого диагностического разрыва.
Поскольку генетические и хронические заболевания продолжают расти во всем мире, ожидается, что спрос на точные и масштабируемые геномные решения, такие как NGS, значительно возрастет, что сделает его краеугольным камнем в будущем современной медицины.

Возможность

«Интеграция искусственного интеллекта (ИИ) в анализ данных NGS»

Инструменты на базе ИИ все чаще интегрируются в рабочие процессы NGS для улучшения анализа данных, автоматизации интерпретации вариантов и обеспечения более точной и действенной информации из геномных данных.
Алгоритмы ИИ могут быстро обрабатывать огромное количество данных секвенирования, идентифицируя генетические мутации, маркеры заболеваний и потенциальные терапевтические цели с большей точностью, помогая клиницистам и исследователям принимать более быстрые и обоснованные решения.
ИИ также повышает эффективность интерпретации генетических данных, автоматизируя обнаружение и классификацию мутаций, уменьшая человеческие ошибки и позволяя проводить крупномасштабные геномные исследования в более короткие сроки.

Например,

В январе 2024 года, согласно исследованию, опубликованному в Nature Medicine, алгоритмы ИИ, обученные на геномных наборах данных, могут предсказать мутации рака с высокой степенью точности, что может революционизировать диагностику и планирование лечения рака, предоставляя персонализированные целевые методы лечения.
В октябре 2023 года в докладе Американского журнала генетики человека было подчеркнуто, что инструменты ИИ оптимизируют анализ генетических расстройств, особенно редких заболеваний, путем повышения способности выявлять ранее упущенные генетические варианты, облегчая более ранние и более точные диагнозы.
Интеграция ИИ в NGS имеет потенциал для преобразования геномного ландшафта, сокращения времени и затрат, связанных с анализом данных, повышения точности диагностики и обеспечения более широкого использования NGS как в клинических, так и в исследовательских условиях.

Сдержанность/вызов

Высокая стоимость платформ и реагентов NGS ограничивает доступность рынка

Высокая стоимость платформ и реагентов секвенирования следующего поколения представляет собой серьезную проблему для широкого внедрения технологий NGS, особенно в условиях ограниченных ресурсов и развивающихся регионах.
Инструменты NGS, которые могут варьироваться от десятков тысяч до нескольких сотен тысяч долларов, наряду с текущими расходами на расходные материалы и реагенты, создают финансовый барьер для небольших лабораторий, больниц и исследовательских учреждений.
Эти существенные первоначальные инвестиции и периодические расходы могут помешать поставщикам медицинских услуг и исследователям принять NGS, что приводит к зависимости от более традиционных и менее эффективных методов генетического тестирования.

Например,

В октябре 2023 года, согласно докладу Международного журнала молекулярных наук, высокие затраты, связанные с НГС, включая расходы на техническое обслуживание и реагенты, ограничивают его доступность в регионах с низким уровнем дохода, влияя на глобальное принятие прецизионной медицины и генетического тестирования.
В результате такие барьеры создают неравенство в доступе к передовой геномной диагностике, что препятствует потенциалу роста рынка, особенно в странах с развивающейся экономикой и небольших клинических условиях.

Секвенирование следующего поколения (NGS)

Рынок сегментирован на основе продукта и услуги, технологии, приложения, конечного пользователя и канала распределения.

Сегментация	Подсегментация
По продуктам и услугам	расходные материалы Услуги Инструменты
По технологии	Секвенирование с помощью синтеза (SBS) Секвенирование по лигации (SBL) Другие
С помощью приложения	Фармацевтическая микробиология Наркотики и биомаркеры Discovery диагностика Точная медицина Исследования в области сельского хозяйства и животных Скрининг пищевых патогенов Другие
Конечный пользователь	Фармацевтические и биотехнологические компании Академические и исследовательские институты Больницы и клиники Клинические лаборатории Контрактные исследовательские организации (CROS) Другие
По каналам распространения	Прямой тендер Розничные продажи Другие

Секвенирование следующего поколения (NGS) Региональный анализ рынка

Северная Америка является доминирующим регионом на рынке секвенирования следующего поколения (NGS).

Северная Америка лидирует на мировом рынке секвенирования следующего поколения (NGS), что обусловлено ее надежной инфраструктурой здравоохранения, ранним внедрением геномных технологий и значительными инвестициями в точную медицину и исследования.
США занимают самую большую долю рынка из-за сильного государственного и частного финансирования исследований в области геномики, растущего спроса на персонализированную терапию и высокой концентрации ведущих компаний и исследовательских институтов NGS.
Наличие благоприятной нормативно-правовой базы, расширение клинического применения NGS и постоянное сотрудничество между биотехнологическими фирмами, академическими учреждениями и поставщиками медицинских услуг продолжают стимулировать региональный рост.
Кроме того, такие инициативы, как исследовательская программа NIH All of Us и растущее использование NGS в онкологии, репродуктивном здоровье и диагностике редких заболеваний, укрепляют позиции США как глобального центра геномных инноваций.

Азиатско-Тихоокеанский регион, по прогнозам, зарегистрирует самый высокий темп роста

Ожидается, что в Азиатско-Тихоокеанском регионе будет наблюдаться самый быстрый рост на рынке NGS, чему способствуют расширение доступа к здравоохранению, повышение осведомленности о генетическом тестировании и увеличение распространенности хронических и наследственных заболеваний.
Такие страны, как Китай, Индия и Япония, становятся основными двигателями роста благодаря растущей государственной поддержке исследований геномики, улучшению диагностической инфраструктуры и повышению доступности технологий секвенирования.
Япония остается лидером в области клинической геномики, особенно в диагностике рака, с сильными правительственными инициативами и растущей экосистемой компаний и исследовательских центров, ориентированных на геномику.
В Китае и Индии масштабные инициативы в области геномики населения, растущие партнерские отношения между местными фирмами и глобальными игроками, а также растущий спрос на раннее и точное выявление заболеваний ускоряют освоение рынка. Эти тенденции в сочетании с увеличением инвестиций в НИОКР делают Азиатско-Тихоокеанский регион ключевым стратегическим направлением для расширения рынка NGS.

Next Generation Sequencing (NGS) Доля рынка

Конкурентный ландшафт рынка предоставляет детали конкурентам. Подробности включают в себя обзор компании, финансовые показатели компании, генерируемые доходы, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, глобальное присутствие, производственные площадки и объекты, производственные мощности, сильные и слабые стороны компании, запуск продукта, ширина и широта продукта, доминирование приложений. Приведенные выше данные касаются только фокуса компаний на рынке.

Основными лидерами рынка, работающими на рынке, являются:

Illumina, Inc. (США)
Thermo Fisher Scientific (США)
Pacific Biosciences of California, Inc. (США)
Oxford Nanopore Technologies (Великобритания)
BGI Group (Китай)
MGI Tech (Китай)
Roche Sequencing Solutions (Швейцария)
Agilent Technologies (США)
PerkinElmer, Inc. (США)
Bio-Rad Laboratories, Inc. (США)
QIAGEN N.V. (Германия)
Genomics PLC (Великобритания)
Genedata (Швейцария)
Roche NimbleGen (Швейцария)
Macrogen, Inc. (Южная Корея)
Novogene Corporation (Китай)
GATC Biotech AG (Германия)
BaseClear B.V. (Нидерланды)
Fasteris SA (Швейцария)
Dovetail Genomics (США)

Последние события на мировом рынке секвенирования следующего поколения (NGS)

В апреле 2024 года Merck KGaA объявила о запуске первого в отрасли комплексного и проверенного анализа генетической стабильности, что ознаменовало значительный прогресс в области безопасности биопроизводства. Недавно представленный Aptegra CHO Genetic Stability Assay объединяет секвенирование всего генома с передовой биоинформатикой, предлагая оптимизированный подход к тестированию генетической стабильности. Это решение «все в одном» предназначено для ускорения оценки биобезопасности, тем самым способствуя более быстрому и эффективному переходу от клинической разработки к серийному производству для биофармацевтических клиентов. Это нововведение имеет большое значение для мирового рынка секвенирования следующего поколения (NGS), поскольку оно подчеркивает растущую интеграцию технологий NGS в биообработку и тестирование биобезопасности.
В январе 2024 года QIAGEN объявила о значительном обновлении своего QIAGEN CLC Genomics Workbench Premium, интегрируя технологию LightSpeed для улучшения поддержки секвенирования следующего поколения (NGS) в вторичном анализе соматического рака. Этот усовершенствованный ускоритель программного обеспечения позволяет быстро преобразовывать исходные данные секвенирования из файлов FASTQ в интерпретируемые генетические варианты данных в формате VCF, обеспечивая результаты с исключительной скоростью и экономичностью. Улучшение укрепляет портфель программного обеспечения QIAGEN NGS, предлагая исследователям и клиницистам более оптимизированное и экономически эффективное решение для анализа соматических мутаций в онкологии. Эта разработка особенно актуальна для глобального рынка NGS, поскольку она отражает растущий спрос на высокоэффективные инструменты биоинформатики, способные обрабатывать сложные геномные данные в клинических приложениях для лечения рака.
В январе 2024 года Beckman Coulter, Inc. объявила о стратегическом партнерстве с Polycarbin, ведущим новатором в области устойчивых лабораторных решений. Сотрудничество направлено на улучшение практики устойчивого развития в автоматизации обработки жидкостей, особенно в использовании и управлении жизненным циклом лабораторных пластмасс. Объединив опыт Beckman Coulter Life Sciences в области автоматизированных технологий обработки жидкостей с платформой циклической экономики Polycarbin, партнерство стремится сократить пластиковые отходы и содействовать экологически ответственным лабораторным операциям. Эта инициатива имеет большое значение для глобального рынка секвенирования следующего поколения (NGS), где высокопроизводительные рабочие процессы секвенирования генерируют значительные объемы пластиковых отходов из-за обширных процессов пипетки и подготовки образцов.
В ноябре 2023 года QIAGEN объявила об успешном сотрудничестве с DNA Labs International в решении двух десятилетий холодных случаев с помощью системы ForenSeq Kintelligence System QIAGEN в сочетании с базой данных GEDmatch PRO. Это достижение подчеркивает растущую эффективность и принятие судебной генетической генеалогии в качестве мощного инструмента для идентификации человека в правоохранительных органах и уголовных расследованиях. Этот прогресс также имеет большое значение для глобального рынка секвенирования следующего поколения (NGS), поскольку он демонстрирует растущую полезность технологий NGS за пределами традиционных клинических и исследовательских областей в судебной науке.
В ноябре 2023 года Beckman Coulter, Inc. объявила о стратегическом сотрудничестве с Pillar Biosciences, ведущим поставщиком решений для тестирования IVD и RUO NGS с использованием собственной технологии SLIMamp. В рамках соглашения Pillar Biosciences разработает набор целевых приложений, разработанных специально для использования в библиотечной системе подготовки библиотек нового поколения Biomek NGeniuS. Это сотрудничество направлено на улучшение решений NGS для рабочих процессов Beckman Coulter путем интеграции передовых геномных анализов Pillar, тем самым поддерживая более эффективные и точные процессы подготовки библиотек. Это сотрудничество имеет большое значение для глобального рынка секвенирования следующего поколения (NGS), поскольку оно подчеркивает растущий акцент на автоматизации, эффективности и клинической полезности в платформах NGS.

SKU-1736

Получите онлайн-доступ к отчету на первой в мире облачной платформе рыночной аналитики

Нажмите на изображение, чтобы увеличить

Интерактивная панель анализа данных
Панель анализа компании для возможностей с высоким потенциалом роста
Доступ аналитика-исследователя для настройки и запросов
Анализ конкурентов с помощью интерактивной панели
Последние новости, обновления и анализ тенденций
Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов

Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 INCREASE IN THE ADOPTION OF GENOME-FOCUSED PHARMACOLOGY

5.1.2 WIDE PRODUCT PORTFOLIO OFFERED BY MAJOR PLAYERS

5.1.3 USE OF NEXT GENERATION SEQUENCING IN DRUG DEVELOPMENT

5.1.4 INCREASE TREND TOWARDS PERSONALIZED MEDICATION

5.2 RESTRAINTS

5.2.1 HIGH COST OF INSTALLATION AND MAINTENANCE OF EQUIPMENT’S IN THE LABORATORY

5.2.2 COMPLEXITY DURING IMPLEMENTATION OF NGS IN THE CLINICAL LAB

5.3 OPPORTUNITIES

5.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYERS

5.3.2 INCREASING ADVANCEMENT IN NGS TECHNOLOGY

5.3.3 INCREASING APPLICATIONS OF NGS IN CLINICAL DIAGNOSTICS

5.4 CHALLENGES

5.4.1 LACK OF SKILLED PROFESSIONALS TO PERFORM NGS

5.4.2 DATA PRIVACY AND SECURITY

6 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT AND SERVICE

6.1 OVERVIEW

6.2 CONSUMABLES

6.2.1 LIBRARY PREPARATION CONSUMABLES

6.2.2 SAMPLE PREPARATION CONSUMABLES

6.3 SERVICES

6.3.1 SEQUENCING SERVICES

6.3.1.1 RNA SEQUENCING

6.3.1.2 DNA SEQUENCING

6.3.1.2.1 WHOLE GENOME SEQUENCING

6.3.1.2.2 WHOLE EXOME SEQUENCING

6.3.1.2.3 TARGETED SEQUENCING

6.3.1.2.4 CHIP SEQUENCING

6.3.1.2.5 DE NOVO SEQUENCING

6.3.1.2.6 OTHERS

6.3.2 DATA MANAGEMENT SERVICES

6.3.2.1 NGS STORAGE, MANAGEMENT AND CLOUD COMPUTING SOLUTIONS

6.3.2.2 NGS DATA ANALYSIS SOFTWARE AND WORKBENCHES

6.3.2.3 NGS DATA ANALYSIS SERVICES

6.4 INSTRUMENTS

6.4.1 BENCHTOP

6.4.2 STANDALONE

6.4.2.1 AUTOMATED

6.4.2.2 SEMI-AUTOMATED

6.4.2.3 MANUAL

6.4.2.3.1 WORKSTATION/PLATFORM

6.4.2.3.2 SYSTEM

7 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY

7.1 OVERVIEW

7.2 SEQUENCING BY SYNTHESIS (SBS)

7.2.1 PYROSEQUENCING

7.2.2 ION SEMI CONDUCTOR SEQUENCING

7.2.3 NANOPORE SEQUENCING

7.2.4 SINGLE-MOLECULE-REAL-TIME SEQUENCING (SMRT)

7.3 SEQUENCING BY LIGATION (SBL)

7.4 OTHERS

8 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 PHARMACEUTICALS MICROBIOLOGY

8.2.1 MICROBIAL IDENTIFICATION/DETECTION

8.2.2 TARGETED SEQUENCING

8.2.3 CELL LINE CHARACTERIZATION

8.2.4 ANTIMICROBIAL RESISTANCE AND PREDICTING ANTIMICROBIAL SUSCEPTIBILITIES

8.2.5 STRAIN SUBTYPING

8.2.6 OTHERS

8.2.6.1 SEQUENCING BY SYNTHESIS (SBS)

8.2.6.2 SEQUENCING BY LIGATION (SBL)

8.2.6.3 OTHERS

8.3 DRUG & BIOMARKER DISCOVERY

8.3.1 SEQUENCING BY SYNTHESIS (SBS)

8.3.2 SEQUENCING BY LIGATION (SBL)

8.3.3 OTHERS

8.4 DIAGNOSTICS

8.4.1 CANCER DIAGNOSTICS

8.4.2 INFECTIOUS DISEASE DIAGNOSTICS

8.4.3 REPRODUCTIVE HEALTH DIAGNOSTICS

8.4.4 OTHER DIAGNOSTIC APPLICATIONS

8.4.4.1 SEQUENCING BY SYNTHESIS (SBS)

8.4.4.2 SEQUENCING BY LIGATION (SBL)

8.4.5 OTHERS

8.5 PRECISION MEDICINE

8.5.1 SEQUENCING BY SYNTHESIS (SBS)

8.5.2 SEQUENCING BY LIGATION (SBL)

8.5.3 OTHERS

8.6 AGRICULTURAL & ANIMAL RESEARCH

8.6.1 SEQUENCING BY SYNTHESIS (SBS)

8.6.2 SEQUENCING BY LIGATION (SBL)

8.6.3 OTHERS

8.7 FOOD PATHOGEN SCREENING

8.8 OTHERS

9 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER

9.1 OVERVIEW

9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

9.3 ACADEMIC & RESEARCH INSTITUTES

9.4 HOSPITALS & CLINICS

9.5 CLINICAL LABORATORIES

9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)

9.7 OTHERS

10 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW

10.2 DIRECT TENDER

10.3 RETAIL SALES

10.3.1 OFFLINE

10.3.2 ONLINE

10.4 OTHERS

11 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 CANADA

11.2.3 MEXICO

11.3 EUROPE

11.3.1 U.K.

11.3.2 GERMANY

11.3.3 FRANCE

11.3.4 SPAIN

11.3.5 ITALY

11.3.6 BELGIUM

11.3.7 RUSSIA

11.3.8 SWITZERLAND

11.3.9 NETHERLANDS

11.3.10 TURKEY

11.3.11 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 AUSTRALIA

11.4.3 JAPAN

11.4.4 INDIA

11.4.5 SINGAPORE

11.4.6 SOUTH KOREA

11.4.7 MALAYSIA

11.4.8 THAILAND

11.4.9 INDONESIA

11.4.10 PHILIPPINES

11.4.11 REST OF ASIA-PACIFIC

11.5 SOUTH AMERICA

11.5.1 BRAZIL

11.5.2 ARGENTINA

11.5.3 REST OF SOUTH AMERICA

11.6 MIDDLE EAST AND AFRICA

11.6.1 SOUTH AFRICA

11.6.2 SAUDI ARABIA

11.6.3 U.A.E.

11.6.4 ISRAEL

11.6.5 REST OF MIDDLE EAST AND AFRICA

12 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILING

14.1 ILLUMINA, INC.

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUEANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 THERMO FISHER SCIENTIFIC INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 QIAGEN

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 MERCK KGAA

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 CHARLES RIVER LABORATORIES

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ACT GENOMICS

14.6.1 COMPANY SNAPSHOT

14.6.2 PRODUCT PORTFOLIO

14.6.3 RECENT DEVELOPMENTS

14.7 AGILENT TECHNOLOGIES, INC.

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 AZENTA US, INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENT

14.9 BECKMAN COULTER, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENTS

14.1 BIO-RAD LABORATORIES, INC.

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 BGI (A SUBSIDIAIRY OF BGI GROUP) (2024)

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 DNASTAR

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 EUROFINS SCIENTIFIC

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENTS

14.14 GILSON INCORPORATED

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 HAMILTON COMPANY

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.16 LGC BIOSEARCH TECHNOLOGIES

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

14.17 MACROGEN, INC.

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 NEW ENGLAND BIOLABS

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 NIMAGEN

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 OXFORD NANOPORE TECHNOLOGIES PLC.

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

14.21 PACBIO.

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENTS

14.22 PCR BIOSYSTEMS

14.22.1 COMPANY SNAPSHOT

14.22.2 PRODUCT PORTFOLIO

14.22.3 RECENT DEVELOPMENTS

14.23 PROMEGA CORPORATION.

14.23.1 COMPANY SNAPSHOT

14.23.2 PRODUCT PORTFOLIO

14.23.3 RECENT DEVELOPMENTS

14.24 QUANTABIO

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENT

14.25 REVVITY

14.25.1 COMPANY SNAPSHOT

14.25.2 REVENUE ANALYSIS

14.25.3 PRODUCT PORTFOLIO

14.25.4 RECENT DEVELOPMENT

14.26 TAKARA BIO INC.

14.26.1 COMPANY SNAPSHOT

14.26.2 REVENUE ANALYSIS

14.26.3 PRODUCT PORTFOLIO

14.26.4 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

Список таблиц

TABLE 1 INSTRUMENT COST PER RUN

TABLE 2 PLATFORM /COMPANY COST PER RUN

TABLE 3 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 13 GLOBAL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 14 GLOBAL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 17 GLOBAL SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 18 GLOBAL SEQUENCING BY LIGATION (SBL) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL OTHERS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL FOOD PATHOGEN SCREENING IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL OTHERS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL ACADEMIC & RESEARCH INSTITUTES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL HOSPITALS & CLINICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL CLINICAL LABORATORIES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL CONTRACT RESEARCH ORGANIZATIONS (CROS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL OTHERS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL DIRECT TENDER IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 46 GLOBAL OTHERS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 47 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 48 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 49 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 50 NORTH AMERICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 51 NORTH AMERICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 52 NORTH AMERICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 53 NORTH AMERICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 54 NORTH AMERICA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 55 NORTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 56 NORTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 57 NORTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 58 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 59 NORTH AMERICA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 60 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 61 NORTH AMERICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 62 NORTH AMERICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 63 NORTH AMERICA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 64 NORTH AMERICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 65 NORTH AMERICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 66 NORTH AMERICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 67 NORTH AMERICA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 68 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 69 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 70 NORTH AMERICA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 71 U.S. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 72 U.S. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 73 U.S. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 74 U.S. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 75 U.S. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 76 U.S. DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 77 U.S. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 78 U.S. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 79 U.S. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 80 U.S. NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 81 U.S. SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 82 U.S. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 83 U.S. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 84 U.S. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 85 U.S. DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 86 U.S. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 U.S. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 88 U.S. PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 89 U.S. AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 90 U.S. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 91 U.S. NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 92 U.S. RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 93 CANADA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 94 CANADA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 95 CANADA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 96 CANADA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 97 CANADA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 98 CANADA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 99 CANADA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 100 CANADA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 101 CANADA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 102 CANADA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 103 CANADA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 104 CANADA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 105 CANADA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 106 CANADA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 107 CANADA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 108 CANADA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 109 CANADA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 110 CANADA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 111 CANADA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 112 CANADA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 113 CANADA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 114 CANADA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 MEXICO NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 116 MEXICO CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 117 MEXICO SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 118 MEXICO SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 119 MEXICO SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 120 MEXICO DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 121 MEXICO INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 122 MEXICO INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 123 MEXICO INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 124 MEXICO NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 125 MEXICO SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 126 MEXICO NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 127 MEXICO PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 128 MEXICO PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 129 MEXICO DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 130 MEXICO DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 131 MEXICO DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 132 MEXICO PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 133 MEXICO AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 134 MEXICO NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 135 MEXICO NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 136 MEXICO RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 137 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 138 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 139 EUROPE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 140 EUROPE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 141 EUROPE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 142 EUROPE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 143 EUROPE DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 144 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 145 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 146 EUROPE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 147 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 148 EUROPE SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 149 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 150 EUROPE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 151 EUROPE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 152 EUROPE DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 153 EUROPE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 154 EUROPE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 155 EUROPE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 156 EUROPE AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 157 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 158 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 159 EUROPE RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 160 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 161 U.K. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 162 U.K. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 163 U.K. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 164 U.K. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 165 U.K. DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 166 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 167 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 168 U.K. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 169 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 170 U.K. SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 171 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 172 U.K. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 173 U.K. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 174 U.K. DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 175 U.K. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 176 U.K. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 177 U.K. PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 178 U.K. AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 179 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 180 U.K. NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 181 U.K. RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 182 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 183 GERMANY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 184 GERMANY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 185 GERMANY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 186 GERMANY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 187 GERMANY DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 188 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 189 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 190 GERMANY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 191 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 192 GERMANY SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 193 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 194 GERMANY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 195 GERMANY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 196 GERMANY DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 197 GERMANY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 198 GERMANY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 199 GERMANY PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 200 GERMANY AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 201 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 202 GERMANY NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 203 GERMANY RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 204 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 205 FRANCE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 206 FRANCE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 207 FRANCE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 208 FRANCE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 209 FRANCE DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 210 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 211 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 212 FRANCE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 213 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 214 FRANCE SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 215 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 216 FRANCE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 217 FRANCE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 218 FRANCE DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 219 FRANCE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 220 FRANCE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 221 FRANCE AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 222 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 223 FRANCE NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 224 FRANCE RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 225 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 226 SPAIN CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 227 SPAIN SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 228 SPAIN SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 229 SPAIN SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 230 SPAIN DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 231 SPAIN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 232 SPAIN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 233 SPAIN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 234 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 235 SPAIN SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 236 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 237 SPAIN PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 238 SPAIN PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 239 SPAIN DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 240 SPAIN DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 241 SPAIN DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 242 SPAIN PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 243 SPAIN AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 244 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 245 SPAIN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 246 SPAIN RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 247 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 248 ITALY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 249 ITALY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 250 ITALY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 251 ITALY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 252 ITALY DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 253 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 254 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 255 ITALY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 256 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 257 ITALY SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 258 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 259 ITALY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 260 ITALY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 261 ITALY DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 262 ITALY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 263 ITALY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 264 ITALY PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 265 ITALY AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 266 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 267 ITALY NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 268 ITALY RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 269 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 270 BELGIUM CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 271 BELGIUM SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 272 BELGIUM SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 273 BELGIUM SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 274 BELGIUM DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 275 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 276 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 277 BELGIUM INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 278 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 279 BELGIUM SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 280 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 281 BELGIUM PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 282 BELGIUM PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 283 BELGIUM DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 284 BELGIUM DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 285 BELGIUM DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 286 BELGIUM PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 287 BELGIUM AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 288 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 289 BELGIUM NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 290 BELGIUM RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 291 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 292 RUSSIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 293 RUSSIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 294 RUSSIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 295 RUSSIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 296 RUSSIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 297 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 298 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 299 RUSSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 300 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 301 RUSSIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 302 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 303 RUSSIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 304 RUSSIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 305 RUSSIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 306 RUSSIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 307 RUSSIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 308 RUSSIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 309 RUSSIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 310 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 311 RUSSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 312 RUSSIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 313 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 314 SWITZERLAND CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 315 SWITZERLAND SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 316 SWITZERLAND SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 317 SWITZERLAND SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 318 SWITZERLAND DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 319 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 320 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 321 SWITZERLAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 322 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 323 SWITZERLAND SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 324 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 325 SWITZERLAND PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 SWITZERLAND PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 327 SWITZERLAND DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 328 SWITZERLAND DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 329 SWITZERLAND DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 330 SWITZERLAND PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 331 SWITZERLAND AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 332 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 333 SWITZERLAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 334 SWITZERLAND RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 335 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 336 NETHERLANDS CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 337 NETHERLANDS SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 338 NETHERLANDS SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 339 NETHERLANDS SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 340 NETHERLANDS DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 341 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 342 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 343 NETHERLANDS INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 344 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 345 NETHERLANDS SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 346 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 347 NETHERLANDS PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 348 NETHERLANDS PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 349 NETHERLANDS DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 350 NETHERLANDS DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 351 NETHERLANDS DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 352 NETHERLANDS PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 353 NETHERLANDS AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 354 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 355 NETHERLANDS NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 356 NETHERLANDS RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 357 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 358 TURKEY CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 359 TURKEY SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 360 TURKEY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 361 TURKEY SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 362 TURKEY DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 363 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 364 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 365 TURKEY INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 366 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 367 TURKEY SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 368 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 369 TURKEY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 370 TURKEY PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 371 TURKEY DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 372 TURKEY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 373 TURKEY DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 374 TURKEY PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 375 TURKEY AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 376 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 377 TURKEY NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 378 TURKEY RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 379 REST OF EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 380 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 381 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 382 ASIA-PACIFIC CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 383 ASIA-PACIFIC SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 384 ASIA-PACIFIC SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 385 ASIA-PACIFIC SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 386 ASIA-PACIFIC DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 387 ASIA-PACIFIC INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 388 ASIA-PACIFIC INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 389 ASIA-PACIFIC INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 390 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 391 ASIA-PACIFIC SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 392 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 393 ASIA-PACIFIC PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 394 ASIA-PACIFIC PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 395 ASIA-PACIFIC DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 396 ASIA-PACIFIC DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 397 ASIA-PACIFIC DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 398 ASIA-PACIFIC PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 399 ASIA-PACIFIC AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 400 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 401 ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 402 ASIA-PACIFIC RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 403 CHINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 404 CHINA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 405 CHINA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 406 CHINA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 407 CHINA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 408 CHINA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 409 CHINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 410 CHINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 411 CHINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 412 CHINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 413 CHINA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 414 CHINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 415 CHINA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 416 CHINA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 417 CHINA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 418 CHINA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 419 CHINA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 420 CHINA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 421 CHINA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 422 CHINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 423 CHINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 424 CHINA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 425 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 426 AUSTRALIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 427 AUSTRALIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 428 AUSTRALIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 429 AUSTRALIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 430 AUSTRALIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 431 AUSTRALIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 432 AUSTRALIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 433 AUSTRALIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 434 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 435 AUSTRALIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 436 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 437 AUSTRALIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 438 AUSTRALIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 439 AUSTRALIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 440 AUSTRALIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 441 AUSTRALIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 442 AUSTRALIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 443 AUSTRALIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 444 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 445 AUSTRALIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 446 AUSTRALIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 447 JAPAN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 448 JAPAN CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 449 JAPAN SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 450 JAPAN SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 451 JAPAN SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 452 JAPAN DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 453 JAPAN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 454 JAPAN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 455 JAPAN INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 456 JAPAN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 457 JAPAN SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 458 JAPAN NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 459 JAPAN PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 460 JAPAN PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 461 JAPAN DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 462 JAPAN DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 463 JAPAN DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 464 JAPAN PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 465 JAPAN AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 466 JAPAN NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 467 JAPAN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 468 JAPAN RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 469 INDIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 470 INDIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 471 INDIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 472 INDIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 473 INDIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 474 INDIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 475 INDIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 476 INDIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 477 INDIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 478 INDIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 479 INDIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 480 INDIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 481 INDIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 482 INDIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 483 INDIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 484 INDIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 485 INDIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 486 INDIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 487 INDIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 488 INDIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 489 INDIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 490 INDIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 491 SINGAPORE NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 492 SINGAPORE CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 493 SINGAPORE SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 494 SINGAPORE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 495 SINGAPORE SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 496 SINGAPORE DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 497 SINGAPORE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 498 SINGAPORE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 499 SINGAPORE INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 500 SINGAPORE NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 501 SINGAPORE SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 502 SINGAPORE NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 503 SINGAPORE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 504 SINGAPORE PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 505 SINGAPORE DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 506 SINGAPORE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 507 SINGAPORE DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 508 SINGAPORE PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 509 SINGAPORE AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 510 SINGAPORE NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 511 SINGAPORE NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 512 SINGAPORE RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 513 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 514 SOUTH KOREA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 515 SOUTH KOREA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 516 SOUTH KOREA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 517 SOUTH KOREA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 518 SOUTH KOREA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 519 SOUTH KOREA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 520 SOUTH KOREA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 521 SOUTH KOREA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 522 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 523 SOUTH KOREA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 524 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 525 SOUTH KOREA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 526 SOUTH KOREA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 527 SOUTH KOREA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 528 SOUTH KOREA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 529 SOUTH KOREA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 530 SOUTH KOREA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 531 SOUTH KOREA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 532 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 533 SOUTH KOREA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 534 SOUTH KOREA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 535 MALAYSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 536 MALAYSIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 537 MALAYSIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 538 MALAYSIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 539 MALAYSIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 540 MALAYSIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 541 MALAYSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 542 MALAYSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 543 MALAYSIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 544 MALAYSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 545 MALAYSIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 546 MALAYSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 547 MALAYSIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 548 MALAYSIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 549 MALAYSIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 550 MALAYSIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 551 MALAYSIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 552 MALAYSIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 553 MALAYSIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 554 MALAYSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 555 MALAYSIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 556 MALAYSIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 557 THAILAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 558 THAILAND CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 559 THAILAND SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 560 THAILAND SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 561 THAILAND SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 562 THAILAND DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 563 THAILAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 564 THAILAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 565 THAILAND INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 566 THAILAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 567 THAILAND SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 568 THAILAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 569 THAILAND PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 570 THAILAND PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 571 THAILAND DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 572 THAILAND DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 573 THAILAND DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 574 THAILAND PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 575 THAILAND AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 576 THAILAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 577 THAILAND NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 578 THAILAND RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 579 INDONESIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 580 INDONESIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 581 INDONESIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 582 INDONESIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 583 INDONESIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 584 INDONESIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 585 INDONESIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 586 INDONESIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 587 INDONESIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 588 INDONESIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 589 INDONESIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 590 INDONESIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 591 INDONESIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 592 INDONESIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 593 INDONESIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 594 INDONESIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 595 INDONESIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 596 INDONESIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 597 INDONESIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 598 INDONESIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 599 INDONESIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 600 INDONESIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 601 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 602 PHILIPPINES CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 603 PHILIPPINES SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 604 PHILIPPINES SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 605 PHILIPPINES SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 606 PHILIPPINES DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 607 PHILIPPINES INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 608 PHILIPPINES INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 609 PHILIPPINES INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 610 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 611 PHILIPPINES SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 612 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 613 PHILIPPINES PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 614 PHILIPPINES PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 615 PHILIPPINES DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 616 PHILIPPINES DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 617 PHILIPPINES DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 618 PHILIPPINES PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 619 PHILIPPINES AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 620 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 621 PHILIPPINES NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 622 PHILIPPINES RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 623 REST OF ASIA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 624 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 625 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 626 SOUTH AMERICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 627 SOUTH AMERICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 628 SOUTH AMERICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 629 SOUTH AMERICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 630 SOUTH AMERICA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 631 SOUTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 632 SOUTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 633 SOUTH AMERICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 634 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 635 SOUTH AMERICA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 636 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 637 SOUTH AMERICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 638 SOUTH AMERICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 639 SOUTH AMERICA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 640 SOUTH AMERICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 641 SOUTH AMERICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 642 SOUTH AMERICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 643 SOUTH AMERICA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 644 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 645 SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 646 SOUTH AMERICA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 647 BRAZIL NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 648 BRAZIL CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 649 BRAZIL SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 650 BRAZIL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 651 BRAZIL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 652 BRAZIL DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 653 BRAZIL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 654 BRAZIL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 655 BRAZIL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 656 BRAZIL NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 657 BRAZIL SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 658 BRAZIL NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 659 BRAZIL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 660 BRAZIL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 661 BRAZIL DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 662 BRAZIL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 663 BRAZIL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 664 BRAZIL PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 665 BRAZIL AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 666 BRAZIL NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 667 BRAZIL NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 668 BRAZIL RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 669 ARGENTINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 670 ARGENTINA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 671 ARGENTINA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 672 ARGENTINA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 673 ARGENTINA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 674 ARGENTINA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 675 ARGENTINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 676 ARGENTINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 677 ARGENTINA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 678 ARGENTINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 679 ARGENTINA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 680 ARGENTINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 681 ARGENTINA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 682 ARGENTINA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 683 ARGENTINA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 684 ARGENTINA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 685 ARGENTINA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 686 ARGENTINA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 687 ARGENTINA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 688 ARGENTINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 689 ARGENTINA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 690 ARGENTINA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 691 REST OF SOUTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 692 MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 693 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 694 MIDDLE EAST & AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 695 MIDDLE EAST & AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 696 MIDDLE EAST & AFRICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 697 MIDDLE EAST & AFRICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 698 MIDDLE EAST & AFRICA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 699 MIDDLE EAST & AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 700 MIDDLE EAST & AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 701 MIDDLE EAST & AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 702 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 703 MIDDLE EAST & AFRICA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 704 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 705 MIDDLE EAST & AFRICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 706 MIDDLE EAST & AFRICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 707 MIDDLE EAST & AFRICA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 708 MIDDLE EAST & AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 709 MIDDLE EAST & AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 710 MIDDLE EAST & AFRICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 711 MIDDLE EAST & AFRICA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 712 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 713 MIDDLE EAST & AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 714 MIDDLE EAST & AFRICA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 715 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 716 SOUTH AFRICA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 717 SOUTH AFRICA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 718 SOUTH AFRICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 719 SOUTH AFRICA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 720 SOUTH AFRICA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 721 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 722 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 723 SOUTH AFRICA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 724 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 725 SOUTH AFRICA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 726 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 727 SOUTH AFRICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 728 SOUTH AFRICA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 729 SOUTH AFRICA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 730 SOUTH AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 731 SOUTH AFRICA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 732 SOUTH AFRICA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 733 SOUTH AFRICA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 734 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 735 SOUTH AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 736 SOUTH AFRICA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 737 SAUDI ARABIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 738 SAUDI ARABIA CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 739 SAUDI ARABIA SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 740 SAUDI ARABIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 741 SAUDI ARABIA SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 742 SAUDI ARABIA DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 743 SAUDI ARABIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 744 SAUDI ARABIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 745 SAUDI ARABIA INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 746 SAUDI ARABIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 747 SAUDI ARABIA SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 748 SAUDI ARABIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 749 SAUDI ARABIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 750 SAUDI ARABIA PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 751 SAUDI ARABIA DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 752 SAUDI ARABIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 753 SAUDI ARABIA DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 754 SAUDI ARABIA PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 755 SAUDI ARABIA AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 756 SAUDI ARABIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 757 SAUDI ARABIA NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 758 SAUDI ARABIA RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 759 U.A.E. NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 760 U.A.E. CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 761 U.A.E. SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 762 U.A.E. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 763 U.A.E. SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 764 U.A.E. DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 765 U.A.E. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 766 U.A.E. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 767 U.A.E. INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 768 U.A.E. NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 769 U.A.E. SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 770 U.A.E. NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 771 U.A.E. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 772 U.A.E. PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 773 U.A.E. DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 774 U.A.E. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 775 U.A.E. DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 776 U.A.E. PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 777 U.A.E. AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 778 U.A.E. NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 779 U.A.E. NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 780 U.A.E. RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 781 EGYPT NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 782 EGYPT CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 783 EGYPT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 784 EGYPT SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 785 EGYPT SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 786 EGYPT DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 787 EGYPT INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 788 EGYPT INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 789 EGYPT INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 790 EGYPT NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 791 EGYPT SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 792 EGYPT NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 793 EGYPT PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 794 EGYPT PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 795 EGYPT DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 796 EGYPT DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 797 EGYPT DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 798 EGYPT PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 799 EGYPT AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 800 EGYPT NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 801 EGYPT NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 802 EGYPT RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 803 ISRAEL NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 804 ISRAEL CONSUMABLES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 805 ISRAEL SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 806 ISRAEL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY SAMPLE, 2022-2031 (USD MILLION)

TABLE 807 ISRAEL SEQUENCING SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY METHOD, 2022-2031 (USD MILLION)

TABLE 808 ISRAEL DATA MANAGEMENT SERVICES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

TABLE 809 ISRAEL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODALITY, 2022-2031 (USD MILLION)

TABLE 810 ISRAEL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY MODE, 2022-2031 (USD MILLION)

TABLE 811 ISRAEL INSTRUMENTS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 812 ISRAEL NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 813 ISRAEL SEQUENCING BY SYNTHESIS (SBS) IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 814 ISRAEL NEXT GENERATION SEQUENCING (NGS) MARKET, BY APPLICATION, 2022-2031 (USD MILLION)

TABLE 815 ISRAEL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 816 ISRAEL PHARMACEUTICALS MICROBIOLOGY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 817 ISRAEL DRUG & BIOMARKER DISCOVERY IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 818 ISRAEL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 819 ISRAEL DIAGNOSTICS IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 820 ISRAEL PRECISION MEDICINE IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 821 ISRAEL AGRICULTURAL & ANIMAL RESEARCH IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY TECHNOLOGY, 2022-2031 (USD MILLION)

TABLE 822 ISRAEL NEXT GENERATION SEQUENCING (NGS) MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 823 ISRAEL NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 824 ISRAEL RETAIL SALES IN NEXT GENERATION SEQUENCING (NGS) MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 825 REST OF MIDDLE EAST AND AFRICA NEXT GENERATION SEQUENCING (NGS) MARKET, BY PRODUCT & SERVICE, 2022-2031 (USD MILLION)

Список рисунков

FIGURE 1 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 2 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: SEGMENTATION

FIGURE 11 INCREASING ADOPTION OF NGS-BASED TESTS IN ONCOLOGY, PRENATAL SCREENING, AND INFECTIOUS DISEASE SURVEILLANCE IS DRIVING THE GROWTH OF THE GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET FROM 2024 TO 2031

FIGURE 12 THE PRODUCT AND SERVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET IN 2024 AND 2031

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR NEXT GENERATION SEQUENCING (NGS) MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET

FIGURE 16 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT AND SERVICE 2023

FIGURE 17 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT AND SERVICES, 2024-2031 (USD MILLION)

FIGURE 18 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY PRODUCT AND SERVICE, CAGR (2024-2031)

FIGURE 19 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET BY PRODUCT AND SERVICE, LIFELINE CURVE

FIGURE 20 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY TECHNOLOGY 2023

FIGURE 21 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY TECHNOLOG, 2024-2031 (USD MILLION)

FIGURE 22 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: BY TECHNOLOG, CAGR (2024-2031)

FIGURE 23 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET BY TECHNOLOG, LIFELINE CURVE

FIGURE 24 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY APPLICATION, 2023

FIGURE 25 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY APPLICATION, 2024-2031 (USD MILLION)

FIGURE 26 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY APPLICATION, CAGR (2024-2031)

FIGURE 27 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY APPLICATION, LIFELINE CURVE

FIGURE 28 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY END USER, 2023

FIGURE 29 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY END USER, 2024-2031 (USD MILLION)

FIGURE 30 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY END USER, CAGR (2024-2031)

FIGURE 31 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY END USER, LIFELINE CURVE

FIGURE 32 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY DISTRIBUTION CHANNEL, 2023

FIGURE 33 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 34 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 35 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 36 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: SNAPSHOT (2023)

FIGURE 37 GLOBAL NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 38 NORTH AMERICA NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 39 EUROPE NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2023 (%)

FIGURE 40 AISA-PACIFIC NEXT GENERATION SEQUENCING (NGS) MARKET: COMPANY SHARE 2023 (%)

View Detailed Information

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Каков текущий размер рынка мирового рынка секвенирования следующего поколения (NGS)?

Объем мирового рынка секвенирования следующего поколения (NGS) в 2024 году оценивался в 15,98 млрд долларов США.

Каковы ожидаемые темпы роста мирового рынка секвенирования следующего поколения (NGS)?

Мировой рынок секвенирования следующего поколения (NGS) вырастет на CAGR 15,10% в течение прогнозируемого периода 2025-2032 годов.

Какие основные сегменты охватываются в глобальном отчете о рынке секвенирования следующего поколения (NGS)?

Рынок секвенирования следующего поколения разделен на пять заметных сегментов на основе продуктов и услуг, технологий, приложений, конечных пользователей и каналов распространения. На основе продукта и услуги рынок подразделяется на расходные материалы, услуги и инструменты. На основе технологии рынок сегментируется на секвенирование путем синтеза (sbs), секвенирование путем лигирования (sbl) и другие. На основе применения рынок сегментирован на фармацевтическую микробиологию, открытие лекарств и биомаркеров, диагностику, прецизионную медицину, сельскохозяйственные и исследования на животных, скрининг пищевых патогенов и другие. На базе конечного потребителя рынок сегментирован на фармацевтические и биотехнологические компании, академические и исследовательские институты, больницы и клиники, клинические лаборатории, подрядные исследовательские организации (кроссы) и другие. На базе конечного потребителя рынок сегментирован на больницы, офтальмологию, клиники, амбулаторные хирургические центры (АСЦ) и другие. На базе канала дистрибуции рынок сегментируется на прямые тендерные, розничные продажи и другие.

Кто является основными игроками на рынке секвенирования следующего поколения?

Такие компании, как Illumina, Inc. (США), Thermo Fisher Scientific (США), Pacific Biosciences of California, Inc. (США), Oxford Nanopore Technologies (Великобритания), BGI Group (Китай), MGI Tech (Китай), Roche Sequencing Solutions (Швейцария), являются основными игроками на рынке секвенирования следующего поколения (NGS).

Каковы последние запуски продуктов крупными компаниями на рынке секвенирования следующего поколения?

В апреле 2024 года Merck KGaA объявила о запуске первого в отрасли комплексного и проверенного анализа генетической стабильности, что ознаменовало значительный прогресс в области безопасности биопроизводства. Недавно представленный Aptegra CHO Genetic Stability Assay объединяет секвенирование всего генома с передовой биоинформатикой, предлагая оптимизированный подход к тестированию генетической стабильности.

Какие страны охватываются рынком секвенирования следующего поколения (NGS)?

Странами, охваченными рынком секвенирования следующего поколения (NGS), являются США, Канада, Мексика, Германия, Франция, Великобритания, Нидерланды, Швейцария, Бельгия, Россия, Италия, Испания, Турция, остальная часть Европы, Китай, Япония, Индия, Южная Корея, Сингапур, Малайзия, Австралия, Таиланд, Индонезия, Филиппины, остальная часть Азиатско-Тихоокеанского региона, Бразилия, Аргентина, остальная часть Южной Америки, Саудовская Аравия, ОАЭ, Южная Африка, Египет, Израиль и остальная часть Ближнего Востока и Африки.

Каковы основные тенденции на рынке секвенирования следующего поколения (NGS)?

Одной из заметных тенденций на мировом рынке секвенирования следующего поколения (NGS) является растущая интеграция искусственного интеллекта (ИИ) и облачных платформ для анализа и интерпретации данных.

Каков доминирующий сегмент на рынке секвенирования следующего поколения (NGS)?

Ожидается, что сегмент расходных материалов будет доминировать на мировом рынке секвенирования следующего поколения (NGS) в 2025 году. Это доминирование объясняется частым использованием расходных материалов, таких как комплекты для обогащения и подготовки образцов, которые необходимы как для исследований, так и для коммерческих применений.

Какой регион является самым быстрорастущим на мировом рынке секвенирования следующего поколения?

Ожидается, что в Азиатско-Тихоокеанском регионе будет наблюдаться самый быстрый рост на рынке NGS, чему способствуют расширение доступа к здравоохранению, повышение осведомленности о генетическом тестировании и увеличение распространенности хронических и наследственных заболеваний.

Каковы факторы, способствующие росту рынка секвенирования следующего поколения (NGS)?

Растущее глобальное бремя генетических расстройств, рака и хронических заболеваний является одним из наиболее значительных факторов, стимулирующих спрос на технологии секвенирования следующего поколения (NGS).

Каковы основные проблемы на рынке секвенирования следующего поколения?

Высокая стоимость платформ и реагентов секвенирования следующего поколения представляет собой серьезную проблему для широкого внедрения технологий NGS, особенно в условиях ограниченных ресурсов и развивающихся регионах.

Какая страна будет доминировать на рынке секвенирования следующего поколения?

Ожидается, что США будут доминировать на рынке секвенирования следующего поколения из-за раннего внедрения геномных технологий.

Какой регион имеет наибольшую долю на мировом рынке секвенирования следующего поколения (NGS)?

Северная Америка лидирует на мировом рынке секвенирования следующего поколения (NGS), что обусловлено ее надежной инфраструктурой здравоохранения и значительными инвестициями в точную медицину и исследования.

В какой стране ожидается самый высокий показатель CAGR на рынке секвенирования следующего поколения (NGS)?

Ожидается, что Китай станет свидетелем самого высокого CAGR на рынке секвенирования следующего поколения (NGS).